The Form 144 signals intent to sell, but the dollar amount is small relative to market cap and may be routine portfolio diversification. Monitor for actual Form 4 filings to confirm execution; the prior August 3 sale was executed, suggesting this one may also proceed. No immediate bearish read-through given the small size and strong analyst consensus.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 12 $26.28entry
- T+1 · 3mo ago −1.71%α −2.41% · $25.83
- T+5 · 3mo ago +0.68%α +1.13% · $26.46
- T+20 · 2mo ago −11.04%α −9.14% · $23.38
- T+60 · 12d ago +2.74%α +7.62% · $27.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Patrick Burnett, an officer of Arcutis Biotherapeutics, filed a Form 144 on August 11, 2026, indicating intent to sell 15,000 shares of common stock with an approximate market value of $397,824.
Key Facts
- Officer Patrick Burnett filed Form 144 to sell 15,000 shares of ARQT common stock.
- Approximate market value of the proposed sale is $397,824.
- The shares were acquired via stock option exercise on January 12, 2024.
- A prior insider sale of 955 shares occurred on August 3, 2026, for $24,941.54.
- ARQT has a market cap of $3.3B and 86% of analysts rate it a Buy or Strong Buy.
Financial Impact
Proposed sale of 15,000 shares valued at ~$398K, representing ~0.01% of market cap.
Risk Factors
- Insider selling could accelerate if additional officers follow suit.
- The stock has shown high volatility historically, with several prior neutral reports seeing large swings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-055797 |
| Document: 0001628280-26-055797-index.html | 0001628280-26-055797 |
| Document: 0001628280-26-055797.txt | 0001628280-26-055797 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers